CD44 and nonpapillary renal cell carcinoma: Finally, while the measurement of the CD44 methylation levels could provide a novel prognostic marker for ccRCC aggressiveness as indicated in this analysis, the publicly available methylation data employed in this work need to be confirmed experimentally for the CD44 gene in an independent ccRCC cohort.